Trevi Therapeutics reports Q 2EPS (7c), consensus (8c)

“Our development plans remain on track in our chronic cough programs and we expect to initiate clinical trials in both chronic cough in IPF and refractory chronic cough in the second half of this year,” said Jennifer Good, President and CEO. “We are currently in the regulatory submission phase in various countries to support trial initiations. We were encouraged by the high degree of scientific and clinical interest at the medical meetings held this quarter surrounding our data generated in chronic cough in IPF and the potential of Haduvio’s mechanism of action to broadly treat chronic cough.”